Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

123
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
123
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

95
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
95

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond FDG PET in Epilepsy: Radiotracers Targeting Neuroreceptors and Neural Proteins.

AJNR. American journal of neuroradiology·2026
Same author

Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

From Training to Independent Practice in Radiology: Reflections and Early-Career Lessons.

Radiology. Imaging cancer·2026
Same author

AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial.

The American journal of gastroenterology·2026
Same author

Thalamic stereoelectroencephalography: safety, accuracy, and thalamocortical connectivity.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical 7T MRI for Epilepsy: A Retrospective Review of 50 Cases.

AJNR. American journal of neuroradiology·2025
Same journal

Prognostic value of perioperative gamma-glutamyl transferase trajectories in perihilar cholangiocarcinoma: a multicentre retrospective cohort study.

Therapeutic advances in medical oncology·2026
Same journal

Clinical significance of high-density lipoprotein cholesterol and its dynamic change in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.

Therapeutic advances in medical oncology·2026
Same journal

CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer.

Therapeutic advances in medical oncology·2026
Same journal

Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis.

Therapeutic advances in medical oncology·2026
Same journal

Serum levels of the C-terminal pro-peptide of type V collagen have prognostic potential and are associated with a normal subtype of desmoplasia in a retrospective cohort of patients with esophagogastric cancer.

Therapeutic advances in medical oncology·2026
Same journal

Exploring the molecular classification-based personalized treatment decision-making in FIGO stage I-III endometrial carcinoma after surgery: a population-based real-world study.

Therapeutic advances in medical oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Clinical practice in prostate PET imaging.

Sean J Huls1, Brian Burkett2, Eric Ehman2

  • 1Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA.

Therapeutic Advances in Medical Oncology
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) imaging for prostate cancer utilizes agents like prostate-specific membrane antigen (PSMA), fluciclovine, and choline. A diverse range of PET radiopharmaceuticals offers flexibility in diagnosis and treatment, especially with PSMA

Keywords:
PET guided treatmentPSMA PET imagingdiagnosisimagingpositron emission tomographyprostate cancerradiotherapy

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

401
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.7K

Related Experiment Videos

Last Updated: Jul 9, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

401
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.7K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical science

Background:

  • Positron emission tomography (PET) imaging has revolutionized prostate cancer management.
  • Targeted radiopharmaceuticals are increasingly vital for diagnosis, staging, and treatment.
  • This review examines common PET agents used in the USA: PSMA, fluciclovine, and choline.

Purpose of the Study:

  • To review the utility of commonly used PET radiopharmaceuticals in prostate cancer.
  • To compare the applications of PSMA, fluciclovine, and choline in various clinical settings.
  • To discuss the advantages and limitations of different PET tracers for prostate cancer.

Main Methods:

  • Narrative review of existing literature.
  • Focus on prostate-specific membrane antigen (PSMA), fluciclovine, and choline.
  • Discussion of utility in screening, staging, recurrence, advanced disease, and pre-therapy evaluation.

Main Results:

  • PET imaging offers advantages over traditional methods in specific scenarios.
  • PSMA agents show promise, particularly at low prostate-specific antigen (PSA) levels.
  • Differences in urinary activity (e.g., high for PSMA) impact image interpretation.

Conclusions:

  • PSMA radiopharmaceuticals are versatile, with diagnostic and therapeutic approvals (e.g., 177Lu-PSMA).
  • A diverse portfolio of PET radiotracers enhances flexibility, crucial during shortages.
  • Maintaining a variety of PET agents for prostate cancer is currently justified.